Miao Yu1, Deng-Chao Wang2, Sheng Li1, Li-Yan Huang3, Jian Wei4. 1. Department of Basic Medicine, Sichuan Vocational College of Health and Rehabilitation, Zigong, Sichuan, China. 2. Department of General Surgery, Zigong Fourth People's Hospital, Zigong, Sichuan, China. wangdengchaopwk@163.com. 3. Department of Pathology, West China Second Hospital of Sichuan University, Chengdu, Sichuan, China. 4. Department of General Surgery, Zigong Fourth People's Hospital, Zigong, Sichuan, China.
Abstract
PURPOSE: The study aims to systematically evaluate the clinical efficacy after 8 weeks (long interval, LI) between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer. METHODS: The PubMed database, EMBASE database, and the Cochrane Library (deadline: September 25, 2021) were searched to select clinical studies that compared two intervals between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer: after 8 weeks (long interval, LI) and within 8 weeks (short interval, SI). The included studies were screened and evaluated according to the inclusion and exclusion criteria, and meta-analysis was performed by RevMan 5.3 software. RESULTS: Eighteen studies were included, with 9070 cases in the LI group and 14,207 cases in the SI group. The analysis results showed that the pathologic complete response (PCR) rate in the LI group was higher than that in the SI group (P < 0.00001). There was no significant difference in the R0 resection rate (P = 0.85), anal preservation rate (P = 0.89), morbidity rate (P = 0.60), anastomotic leakage rate (P = 0.06), operation time (P = 0.58), local recurrence rate (P = 0.56), distant metastasis rate (P = 0.32), or overall survival (OS) rate (P = 0.17) between the two groups. CONCLUSION: A longer interval between neoadjuvant chemoradiotherapy and surgery can improve the PCR rate; however, it has no significant impact on the clinical efficacy or long-term prognosis. Due to some limitations in the number and quality of the studies, these findings still need to be further verified by multicenter, large-sample high-quality RCTs in the future.
PURPOSE: The study aims to systematically evaluate the clinical efficacy after 8 weeks (long interval, LI) between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer. METHODS: The PubMed database, EMBASE database, and the Cochrane Library (deadline: September 25, 2021) were searched to select clinical studies that compared two intervals between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer: after 8 weeks (long interval, LI) and within 8 weeks (short interval, SI). The included studies were screened and evaluated according to the inclusion and exclusion criteria, and meta-analysis was performed by RevMan 5.3 software. RESULTS: Eighteen studies were included, with 9070 cases in the LI group and 14,207 cases in the SI group. The analysis results showed that the pathologic complete response (PCR) rate in the LI group was higher than that in the SI group (P < 0.00001). There was no significant difference in the R0 resection rate (P = 0.85), anal preservation rate (P = 0.89), morbidity rate (P = 0.60), anastomotic leakage rate (P = 0.06), operation time (P = 0.58), local recurrence rate (P = 0.56), distant metastasis rate (P = 0.32), or overall survival (OS) rate (P = 0.17) between the two groups. CONCLUSION: A longer interval between neoadjuvant chemoradiotherapy and surgery can improve the PCR rate; however, it has no significant impact on the clinical efficacy or long-term prognosis. Due to some limitations in the number and quality of the studies, these findings still need to be further verified by multicenter, large-sample high-quality RCTs in the future.
Authors: Julio Garcia-Aguilar; David D Smith; Karin Avila; Emily K Bergsland; Peiguo Chu; Richard M Krieg Journal: Ann Surg Date: 2011-07 Impact factor: 12.969
Authors: Megan C Turner; Jeffrey E Keenan; Christel N Rushing; Brian C Gulack; Daniel P Nussbaum; Ehsan Benrashid; Terry Hyslop; John H Strickler; Christopher R Mantyh; John Migaly Journal: J Gastrointest Surg Date: 2019-01-11 Impact factor: 3.452
Authors: E Akgun; C Caliskan; O Bozbiyik; T Yoldas; M Sezak; S Ozkok; T Kose; B Karabulut; M Harman; O Ozutemiz Journal: Br J Surg Date: 2018-08-29 Impact factor: 6.939
Authors: Jessica Evans; Diana Tait; Ian Swift; Kjell Pennert; Paris Tekkis; Andrew Wotherspoon; Ian Chau; David Cunningham; Gina Brown Journal: Dis Colon Rectum Date: 2011-10 Impact factor: 4.585
Authors: Roger Marr; Kevin Birbeck; James Garvican; Christopher P Macklin; Nicholas J Tiffin; Wendy J Parsons; Michael F Dixon; Nicholas P Mapstone; David Sebag-Montefiore; Nigel Scott; David Johnston; Peter Sagar; Paul Finan; Philip Quirke Journal: Ann Surg Date: 2005-07 Impact factor: 12.969
Authors: Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Lynette Cederquist; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Evan Wuthrick; Kristina M Gregory; Lisa Gurski; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2018-07 Impact factor: 11.908
Authors: Ali Akbar; Abu Bakar Hafeez Bhatti; Samiullah Khan Niazi; Amir Ali Syed; Shahid Khattak; Syed Hassan Raza; Ather Saeed Kazmi Journal: Asian Pac J Cancer Prev Date: 2016
Authors: J D Foster; P Ewings; S Falk; E J Cooper; H Roach; N P West; B A Williams-Yesson; G B Hanna; N K Francis Journal: Tech Coloproctol Date: 2016-08-10 Impact factor: 3.781
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18